Thursday 20 December 2012
SLC45A3; solute carrier family 45, member 3; PCANAP2, PCANAP6, PCANAP8, "prostate cancer associated protein 2", "prostate cancer associated protein 6", "prostate cancer associated protein 8"; IPCA-2, IPCA-6, IPCA-8, prostein; 1q32.1
In cancer tissue, ERG protein expression showed a high rate of concordance with an underlying ERG rearrangement (91.5%).
Importantly, SLC45A3 down regulation was significantly associated with shorter PSA-free survival times. (22821757)
In contrast, TMPRSS2 was neither differentially expressed nor did it show a correlation between protein expression and rearrangement status. (22821757)
Moreover, these cases may represent a distinct molecular subclass of ERG rearranged prostate cancer with distinct clinical features. (22821757)
Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G. Int J Cancer. 2012 Jul 23. PMID: 22821757